Recently, (Chinese trade name: 因他瑞®) of Yingli Pharma has been approved with condition for marketing through the priority review and approval procedure by NMPA in China. This product is an innovative drug with independent intellectual property rights, of which the research and development is taken independently in China. Linperlisib tablet is approved for the treatment of relapsed/refractory follicular lymphoma adult patients who have received two or more prior systemic therapies.

　　Linperlisib is a phosphoinositide 3-kinase delta (PI3Kδ) selective inhibitor. It is able to reduce the level of phosphorylated AKT protein by inhibiting PI3Kδ protein, thereby inducing apoptosis and inhibiting the proliferation of malignant B cells and primary tumor cells. The marketing of this product provides a treatment option for relapsed/refractory follicular lymphoma adult patients who have no other existing treatment options.